drugset / Trial / NCT06107686

A Study of YL202 in Selected Patients With Advanced Solid Tumors

NCT06107686

Phase 2 Recruiting 200 enrolled MediLink Therapeutics (Suzhou) Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.

Timeline

Start
2023-12-15
Primary completion
2026-11
Completion
2028-11

Drugs

EvaluationDrugModalityDoseRoute
Subject YL202 Unknown Intravenous